Biotech & Genomic Medicine › RNA Therapeutics ▲Capital
Biotech & Genomic Medicine › mRNA Platforms ▲Capital
NOVN.SW · Capital · Positive Novartis signs $7.8B licensing/option deal with Abogen for RNA therapeutics, adding pipeline assets amid generic competition and pipeline setbacks
Abogen Biosciences · Capital · Positive Abogen receives $575M upfront and up to ~$7.2B in milestones plus royalties under the Novartis licensing and option agreement
Artificial Intelligence › AI Compute & Accelerator Silicon Competition
Reflection AI · Competition · Positive Nvidia-backed Reflection is pitching its open weight model as a domestic alternative for companies wanting custom AI without relying on Chinese-based models.
NVDA · Competition · Negative US AI lead over China narrows to 3% as Chinese labs advance despite Nvidia's best chips being cut off, and Reflection pitches an open-weight domestic alternative to Chinese models.
ADM · Demand · Positive China's 25 million ton U.S. soybean purchase commitment and ~1 million tons/week buying support ADM's grain merchandising, origination and transportation volumes.
Artificial Intelligence › Foundation Models & Research Labs Technology
Artificial Intelligence › Open-Weight Model Developers Technology
Cybersecurity & Digital Trust › AI Security & Agent Guardrails Technology
Artificial Intelligence › AI Tooling, Data & MLOps Technology
Hirundo · Technology · Positive Hirundo released its Westernized Qwen models and plans to publish its CCPC-500 benchmark, showcasing its machine-unlearning technology
9988.HK · Technology · Negative Hirundo released Westernized versions of Alibaba's Qwen models with CCP alignment stripped from the weights, undermining Alibaba's model positioning
QCOM · Regulation · Positive Qualcomm signs a multi-year 5G/AI patent cross-license with Huawei and will buy certain Huawei US patents, subject to regulatory approvals.
Huawei · Regulation · Positive Huawei secures a multi-year cross-license with Qualcomm and sells certain US patents, with its IP licensing business generating positive revenue since 2021.
Teikoku Databank, Ltd. · · Neutral Teikoku Databank is cited as the data source for the record-low count of Japanese firms in China; no impact on its own business.
Electrification & Mobility › China NEV Leaders ▲Competition
002594.CS · Demand · Positive BYD became Argentina's ninth-largest auto brand by sales since entering in late 2025, with Chinese brands' share reaching 10%.
0175.HK · Demand · Positive Geely exhibited at Argentina's first Chinese auto show as Chinese brands' sales share surged to 10% on duty-free EV import measure.
601633.CG · Demand · Positive Great Wall Motor exhibited at Argentina's first Chinese auto show as Chinese brands' sales share surged to 10%.
9973.HK · Demand · Positive Chery exhibited at Argentina's first Chinese auto show amid Chinese brands' sales share rising from 2% to 10%.
Electrification & Mobility › China NEV Leaders ▼Demand
9866.HK · Demand · Negative Q3 deliveries of 109,178 grew only 25.4% year over year, a slowdown pointing to moderating operational momentum and pressure on margin improvement.
DQ · Capital · Neutral Fair value cut ~18% with JPMorgan Overweight ($22 target) vs Goldman Sell ($10 target) after Q2 non-GAAP net loss on lower ASPs and higher SG&A.
DQ · Tariff · Negative US government preparing a polysilicon price floor and tariffs, with Daqo cited among companies expected to be affected.
688303.CG · Capital · Neutral Parent Daqo New Energy's fair value cut and split analyst ratings (JPMorgan Overweight vs Goldman Sell) after a Q2 net loss.
688303.CG · Tariff · Negative US polysilicon price floor and tariffs cited as affecting Daqo New Energy, the parent of Xinjiang Daqo.
Vor Biopharmaは、中国で実施された第3相試験の事後解析を報告した。それによると、テリタセプトは全身型重症筋無力症の成人患者において、深く持続的な臨床的奏効をもたらし、48週間にわたり概ね良好な忍容性を示した。解析では、最小症状発現に到達した患者の大半がその状態を維持し、残りの追跡期間の多くをこの状態で過ごしたことが強調された。新たなデータは奏効の深さと持続性を裏付けるものの、主要な近接カタリストである2027年のUPSTREAMグローバル第3相試験のトップライン結果や、グローバルデータがこれまでの中国での経験と一致しない可能性があるという中心的リスクを実質的に変えるものではない。この結果は、Vorが2026年9月初旬にグローバルUPSTREAM第3相gMG試験の組み入れを完了したことと並ぶものである。Vor Biopharmaの見通しでは、2029年までに売上高1億1100万ドル、利益1910万ドルを計上し、現在の6億2780万ドルから6億870万ドルの減益となると示唆され、適正価値は39ドル、現在の株価に対して109%の上昇余地があると予測している。
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics Technology
VOR · Technology · Positive Post hoc Phase 3 analysis shows telitacicept produced deep, durable responses over 48 weeks in generalized myasthenia gravis, reinforcing the drug's clinical profile.
300364.CS · Capital · Negative Shenzhen Stock Exchange questions Chinese Online's 2.833 billion yuan private placement, which is over 10 times its net assets, raising financing and valuation concerns.
601500.CG · Pricing · Positive General Science Technology is a named leader raising prices 2%-5% across all categories, citing raw-material cost inflation
601058.CG · Pricing · Positive Sailun Tire is named among leading tire makers implementing a 2%-5% all-category price hike, lifting its product prices
601966.CG · Pricing · Positive Linglong Tire is named among leading tire companies implementing the 2%-5% all-category price increase
603049.CG · Pricing · Positive Zhongce Rubber is named among leading tire makers raising prices 2%-5% across all product categories
康希諾生物は国慶節連休前の最終取引日に力強くストップ高となり、株価は前期の保ち合いレンジを突破し、2023年4月以来の高値を更新した。H株も連動して上昇した。10月1日、康希諾生物は株価の異常変動に関する公告を発表し、最近の市場におけるmRNA技術の発展や、海外のmRNA腫瘍ワクチンの臨床段階データの公表または公表計画に注目していると明らかにした。康希諾生物は、mRNAプラットフォームは同社が布局する技術プラットフォームの一つであり、mRNA予防用ワクチンおよび治療用バイオ医薬品の開発、ならびに関連する送達システムの開発を進めていると明確に述べた。治療領域では、膠芽腫、横紋筋肉腫、子宮頸がんなどの適応症を対象としたmRNAワクチンの研究開発、およびIn Vivo CAR関連療法の開発を進めているが、いずれも現在は初期段階にある。今年8月、メルクとモデルナは、個別化メッセンジャーRNA抗がんワクチンが第III相試験で主要評価項目を達成したと共同発表した。これは大規模第III相臨床試験で有効性が証明された世界初の治療用ワクチンである。8月25日、康希諾生物の公式WeChatアカウントは、子会社の康希諾生物上海バイオ研究開発有限公司が德普世杭州生物科技有限責任公司と「mRNA個別化治療用腫瘍ワクチン共同開発戦略協力枠組み協定」を正式に締結したと発表した。両社はmRNA個別化治療用腫瘍ワクチンの研究開発と商業化を共同で推進し、消化管固形腫瘍および希少腫瘍の治療領域に焦点を当て、世界市場を視野に入れる。なお、現在の康希諾生物のmRNA全製品はまだ初期研究開発段階を脱しておらず、革新的医薬品の研究開発には技術的失敗、臨床試験の期待未達、承認遅延など複数の不確実性が存在し、国内のmRNAワクチン分野の競争も日増しに激しくなっている。
688185.CG · Technology · Neutral CanSino clarified its mRNA cancer vaccine programs (glioblastoma, rhabdomyosarcoma, cervical cancer, In Vivo CAR) remain in early stages despite the stock's limit-up.
德普世(杭州)生物科技有限责任公司 · Demand · Positive Depush Hangzhou signed a strategic cooperation framework agreement with CanSino Shanghai Biologics to jointly develop personalized therapeutic mRNA cancer vaccines.
MRK · Technology · Positive Merck's partnered personalized mRNA cancer vaccine met its primary endpoint in a Phase III trial, the first such therapeutic vaccine success.
MRNA · Technology · Positive Moderna's jointly announced personalized mRNA cancer vaccine met its primary endpoint in a Phase III trial.
SOYBEAN · Tariff · Negative China left the 10% tariff on US soybeans in place and excluded them from the $30B tariff-cut list, keeping Chinese buyers hesitant and pressuring US soybean demand.
P911.XETRA · Capital · Negative HSBC estimates the combustion-Macan timing gap will cost ~25,000 units and ~€500M profit in 2027, with operating profit forecast to fall 8%.
P911.XETRA · Demand · Negative Electric Macan sales fell 40% and Taycan deliveries dropped 25%, with China deliveries down 32%, driving the gas-engine pivot.
VOW.XETRA · Capital · Negative Volkswagen takes a ~€6B non-cash goodwill impairment tied to Porsche.
VOW3.XETRA · Capital · Negative Volkswagen takes a ~€6B non-cash goodwill impairment tied to Porsche.
PAH3.XETRA · Capital · Negative As Porsche's controlling shareholder, it is exposed to the ~€6B Volkswagen goodwill impairment tied to Porsche and Porsche's profit decline.
688836.CG · Demand · Positive BTIG estimates Unitree built ~31K humanoids with 2026 shipments to at least double from ~6,000 in 2025, and plans 30K annual capacity.
智元机器人 · Demand · Positive BTIG estimates AgiBot (智元机器人) is a major player in the half-size humanoid build, contributing to the ~31K cumulative units through June.
TSLA · Technology · Neutral BTIG says Tesla is the key potential challenger to half-size dominance, with Optimus production anticipated at Fremont later in 2026 but slow initial output due to ~10K unique parts.
1X Technologies · Technology · Neutral 1X Technologies is mentioned only as a key player for a potential future shift to full-size systems, with no concrete development.
Boston Dynamics · Technology · Neutral Boston Dynamics is named only as one of the key players if the industry shifts toward full-size systems, with no specific development.
300957.CS · Capital · Positive Company launched its first interim dividend of 1.50 yuan per 10 shares and had cumulatively repurchased 3.6997 million shares for ~120 million yuan.
300957.CS · Technology · Positive Betaini's first self-developed Class III medical device BTN001 (sodium hyaluronate injectable) received NMPA approval, opening a second growth curve.
300909.CS · Capital · Positive Huichuangda plans a cash acquisition of 100% equity in Chuncao Technology, which will become a wholly-owned consolidated subsidiary.
东莞市春草研磨科技有限公司 · Capital · Positive Chuncao Technology is being fully acquired by Huichuangda in cash, becoming its wholly-owned subsidiary.
NKE · Capital · Negative Morgan Stanley cut Nike's price target to 27 from 31, citing embedded high-single-digit sales declines and further de-rating risk.
NKE · Supply · Negative Excess inventory in North America and a similar dynamic in China are pressuring Nike's outlook.
MS · Capital · Neutral Morgan Stanley is the analyst firm cutting Nike's price target, an action about Nike rather than a development affecting Morgan Stanley itself.
NKE · Capital · Negative Nike issued weaker-than-expected FY2027 guidance with adjusted EPS of $1.15-$1.35 versus $1.68 consensus and high-single-digit revenue decline.
NKE · Demand · Negative Nike reported a 4.3% year-on-year sales decline to $11.21 billion, missing revenue expectations amid product challenges and an ailing China business.
NKE · Capital · Negative Nike is cutting jobs and overhauling the business as results deteriorate, with a $2.5B cost-savings plan carrying $1B in restructuring costs.
NKE · Demand · Negative Sportswear and Jordan sales are down and China plunged 26% in the latest quarter, with the remaining problem described as product-led.
Artificial Intelligence › AI Applications & Copilots ▲Technology
IQ · Demand · Positive iQIYI's AIGC film series The Ferry Man surpassed RMB 8 million in revenue-sharing, with the first two titles recovering full production costs within a week.
GHY Culture & Media · Demand · Positive Co-produced iQIYI's AIGC film series The Ferry Man, which surpassed RMB 8 million in revenue-sharing and recovered production costs.
Artificial Intelligence › AI Applications & Copilots ▲Technology
Artificial Intelligence › Agentic AI & Autonomous Workflows ▲Technology
Black Lake Technologies · Demand · Positive Black Lake's PopZao platform connects factories with the creator economy, with an early customer selling out 500 units, signaling real product adoption.